Mirazid in treatment of human hymenolepiasis.
The efficacy and safety of Mirazid in treatment of human hymenolepiosis were carried out in a rural village in Talkha Center (Dakahlia G.). Kato thick smear stool examination showed 51 cases of Hymenolepis nana (9 of them had concomitant parasitosis), two cases of H. dimninuta. Mirazid was given in a dose of 10 mg/kg/d for nine consecutive days an hour before breakfast for hymenolepiosis cases, as capsule for adults and suppository for children. All cases were subjected to history taking before treatment and six weeks post-treatment and stool examination was repeated as well weekly for six weeks post-treatment. There was overt clinical improvement. Side effects were negligible. Parasitologic cure rate was 40/41 or 95.2% for H. nana one week post-treatment, and 100% for H. diminuta one week post-treatment, up to six weeks follow-up for all treated patients. Two unresponded H. nana patients were cured by another Mirazid course.